A profound mismatch has quietly undermined the promise of Alzheimer's early detection: blood tests can now identify disease pathology years before symptoms emerge, yet the clinical evaluations used to act on those results were designed to catch late-stage decline. Bridging that gap may be the next pivotal advance in dementia care.
Published in Nature Aging, this perspective argues that plasma biomarkers — including phosphorylated tau and amyloid-beta ratios — have outpaced the sensitivity of conventional neuropsychological tools such as the MMSE and MoCA. These standardized batteries were optimized to detect moderate cognitive impairment, not the subtle, early functional changes that precede it by years. The authors advocate for digital cognitive assessments specifically engineered to probe Alzheimer's-disease-vulnerable neural circuits — including hippocampal-dependent episodic memory, spatial navigation, and processing speed — systems that deteriorate measurably before a patient would fail a clinic-based test. The integration of such tools with plasma biomarker profiles, the argument goes, could dramatically sharpen prognostic accuracy.
This framing reflects a genuine tension building across the dementia research field. The commercial availability of blood-based Alzheimer's tests has accelerated faster than the clinical infrastructure to interpret them. Digital assessments, administered via tablet or smartphone and capable of capturing granular reaction-time and error-rate data, offer a scalable solution — but the evidence base for their clinical validity remains uneven. Most validation studies involve relatively small, highly educated, and predominantly white cohorts, raising real concerns about generalizability across age groups and literacy levels. Furthermore, this is a perspective piece rather than an original clinical trial, meaning the recommendation rests on synthesis and expert judgment rather than new outcome data. Still, the directional logic is sound and increasingly urgent: as disease-modifying therapies enter clinical use, identifying candidates at the earliest possible stage becomes a therapeutic — not merely academic — imperative.
